Last reviewed · How we verify
DTPw-HBV/Hib-MenAC conjugate vaccine
This combination vaccine stimulates immune responses against diphtheria, tetanus, pertussis, hepatitis B, Haemophilus influenzae type b, and Neisseria meningitidis serogroups A and C through conjugate technology.
This combination vaccine stimulates immune responses against diphtheria, tetanus, pertussis, hepatitis B, Haemophilus influenzae type b, and Neisseria meningitidis serogroups A and C through conjugate technology. Used for Prevention of diphtheria, tetanus, pertussis, hepatitis B, Haemophilus influenzae type b, and Neisseria meningitidis serogroups A and C in infants and children.
At a glance
| Generic name | DTPw-HBV/Hib-MenAC conjugate vaccine |
|---|---|
| Sponsor | GlaxoSmithKline |
| Drug class | Combination conjugate vaccine |
| Modality | Biologic |
| Therapeutic area | Immunology / Infectious Disease |
| Phase | Phase 3 |
Mechanism of action
The vaccine contains inactivated toxoids (diphtheria, tetanus), acellular pertussis antigens, recombinant hepatitis B surface antigen, and polysaccharide conjugates from Hib and meningococcal serogroups A and C linked to carrier proteins. This conjugate approach enhances immunogenicity by promoting T-cell dependent responses, enabling protection in infants and young children against these six major bacterial pathogens.
Approved indications
- Prevention of diphtheria, tetanus, pertussis, hepatitis B, Haemophilus influenzae type b, and Neisseria meningitidis serogroups A and C in infants and children
Common side effects
- Injection site reactions (pain, redness, swelling)
- Fever
- Irritability
- Drowsiness
- Loss of appetite
Key clinical trials
- Safety Study of a Vaccine Against Meningitis in Infants ( 2,4 & 6 Months Age) After a Birth Dose of Hepatitis B. (PHASE3)
- Safety Study of a Vaccine Against Meningitis in Infants (2,4 & 6 Months Age) After a Birth Dose of Hepatitis B. (PHASE3)
- Assess the Immune Response Following Primary Vaccination With GSK Biologicals' Tritanrix™-HepB/Hib-MenAC vs Tritanrix™-HepB/Hiberix™ Given at 6,10 & 14 Wks of Age to Infants Who Received Hepatitis B Vaccine at Birth (PHASE3)
- Immunogenicity & Safety Study of a Vaccine Against Meningitis in Infants (2,4,6 Months) After a Hepatitis B Birth Dose. (PHASE3)
- Assess if Immune Response of GSK Biologicals' Tritanrix™-HepB/Hib-MenAC Given Without or With Hepatitis B Vaccine at Birth is at Least as Good as Tritanrix™-HepB/Hiberix™ Without Hepatitis B Vaccine at Birth, When Given to Healthy Infants (PHASE3)
- A Study to Assess Antibody Persistence, Boostability & Safety in Previously Primed Subjects. (PHASE2)
- Assess Immune Response Following Primary Vaccination With Tritanrix™-HepB Vaccine Mixed With 3 Formulations of Hib-MenAC Vaccine to Infants (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- DTPw-HBV/Hib-MenAC conjugate vaccine CI brief — competitive landscape report
- DTPw-HBV/Hib-MenAC conjugate vaccine updates RSS · CI watch RSS
- GlaxoSmithKline portfolio CI